FAQs

The 9th Neuropsychiatric Drug Development Summit is the industry’s flagship, end to end forum dedicated to transforming the development of next generation mental health therapies. Taking place in September 2026, the meeting unites 150+ senior leaders across discovery, preclinical, translational, clinical, regulatory and investment functions to address the biggest barriers facing psychiatric drug development — including placebo response, patient heterogeneity, endpoint subjectivity, and late stage failure.

The summit is built around advancing precision psychiatry, with a strong focus on biology driven development, EEG and sleep biomarkers, patient stratification, novel endpoints, and regulatory ready clinical strategies.

The conference will be held in person in Boston, Massachusetts, at the Revere Hotel Boston, located at 200 Stuart Street, Boston, MA 02116.

Boston was selected as a global hub for neuroscience, psychiatry, and biopharma innovation, making it an ideal setting for high level collaboration and networking.

You can expect to meet a highly technical, senior level audience, including:

• Discovery, translational and clinical leaders from pharma and biotech
• CMOs, medical directors, and clinical program leads
• Regulatory and former FDA decision makers
• Biomarker, EEG, AI, and digital health experts
• Academic thought leaders and clinician scientists
• Investors, venture capitalists, and business development leaders
• CROs and solution providers focused on CNS development

Attending and speaking organizations include AbbVie, Lundbeck, Boehringer Ingelheim, Otsuka, Neumora, Compass Pathways, Johnson & Johnson, Bristol Myers Squibb, Gilgamesh Pharmaceuticals, Monument Therapeutics, Alkermes, Karuna Therapeutics, and many more.

The agenda spans the full neuropsychiatric drug development lifecycle, with key themes including:

• Precision Psychiatry: Moving from symptom based diagnosis to biology first frameworks using EEG, genetics, molecular biomarkers, and AI
• EEG & Sleep Biomarkers: Standardization, predictivity, AI utility, and regulatory alignment
• Neuroplastogens, Psychedelics & Rapid Acting Antidepressants: Mechanisms of neuroplasticity, ketamine derived agents, and non hallucinogenic approaches
• Muscarinic Innovation: M1/M4 pathways, PAMs, and lessons from recent approvals
• Modernizing Preclinical Models: Genetics anchored models, circuit level readouts, and translational predictivity
• Novel Endpoints & COAs: Digital biomarkers, speech analytics, sleep measures, and regulatory ready endpoints
• Clinical & Regulatory Strategy: Overcoming the Phase II/III roadblock, placebo mitigation, and global trial execution
• Investment & Partnering: Deal making, BD strategy, and what investors look for in neuropsychiatric assets

This summit is intentionally designed to be:

• Deeply technical rather than high level or promotional
• Focused exclusively on neuropsychiatric drug development, not general CNS
• Cross functional, spanning discovery through regulatory and commercialization
• The right size for meaningful discussion, practical learning, and real collaboration

With dedicated EEG focus content, expanded regulatory participation, and data‑driven case studies from recent successes and failures, the summit prioritizes actionable insight over speculation.

As a delegate, you will:

• Learn how leading companies are de‑risking neuropsychiatric pipelines
• Gain practical insight into biomarkers, endpoints, and patient stratification
• Hear candid lessons from late‑stage successes and failures
• Benchmark your programs against peers across pharma and biotech
• Network with senior decision‑makers in a highly targeted environment
• Leave with strategies you can immediately apply to ongoing or upcoming programs

You can register directly via the official summit website. Multiple pass options are available, including conference only passes and conference plus workshop or focus day packages. Early registration offers savings of up to $500, subject to deadlines.

Explore registration options here.

Sponsoring the summit allows you to:

• Position your company as a partner of choice in neuropsychiatric R&D
• Engage directly with decision‑makers actively seeking solutions
• Showcase your capabilities across EEG, biomarkers, CRO services, digital tools, or translational platforms
• Access curated 1‑to‑1 meetings and high‑value networking opportunities
• Increase visibility before, during, and after the event

Partnerships are customizable to align with your strategic goals and target audience.

The summit runs from September 15–17, 2026 and includes:

Pre‑Conference Day (September 15):

• EEG Focus Day
• Deep‑dive workshops on novel endpoints, precision psychiatry, EEG & sleep biomarkers, and interventional psychiatry commercialization

Main Conference Days (September 16–17):

• Two concurrent tracks: Preclinical & Translational and Clinical & Regulatory
• Keynotes, panels, data‑driven presentations, roundtables, poster session, and extensive networking time

Explore the full agenda here.

Yes. Group discounts are available for organizations registering multiple delegates.

Discounts apply when three or more delegates from the same company register and pay at the same time, with increased savings for larger groups.

Explore registration options here.

Yes. Discounted academic and research rates are available for full time academics and researchers. Eligibility criteria apply, and bookings are subject to approval.

Explore registration options here.

For questions about registration, sponsorship, pricing, or eligibility, you can contact the NPD team directly:

Email: info@hansonwade.com

The team will be happy to support any queries related to attending, partnering, or speaking opportunities.

For sponsor related queries: sponsor@hansonwade.com